Jun 16, 2021 / 07:00PM GMT
Jason Nicholas Butler - JMP Securities LLC, Research Division - MD, Director of Healthcare Research & Equity Research Analyst
Great. Well, thank you again for joining us this afternoon at the JMP Securities Life Science Conference. Excited to have Cortexyme join us next and the company's CEO, Casey Lynch. Casey, welcome, really appreciate you being here.
Obviously, a really exciting year for Cortexyme with the Phase III -- Phase II/III GAIN study. It's still on track to read out in 4Q. Also, obviously, as Tom talked about in the Alzheimer's world and how that recent FDA decision could impact you, you guys and everybody else, and would love to get your thoughts there. But maybe let's just start off with a high-level overview. If you could just give us a quick 30-second overview of Cortexyme and the work you're doing in the Alzheimer's space.
Casey C. Lynch - Cortexyme, Inc. - Co-Founder, Chairman, President & CEO
Yes, absolutely. We have a new approach to Alzheimer's, which we believe is upstream of not only the amyloid plaques and the tau
Cortexyme Inc at JMP Securities Life Sciences Virtual Conference Transcript
Jun 17, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers